AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma

Recruitingn/aAges 18 Years - anyAllFondazione IRCCS Istituto Nazionale dei Tumori, Mโ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to better understand why some people with metastatic adenoid cystic carcinoma (ACC) of the head and neck have slow-growing disease while others have faster-growing or more aggressive disease. Researchers want to learn how the biology of the tumor relates to each person's clinical risk group, which is based on a published prediction tool (a nomogram). The main question the study aims to answer is: Do people in the high-risk and low-risk groups have different biological tumor types (called ACC-I and ACC-II) when their primary tumor is tested? The study will also look at other important questions, such as: * Do metastatic tumors show the same biological type as the original tumor? * Do biological types differ based on where metastases grow or how early or late they appear? * Are biological types linked to how well systemic treatments work? * Can bl

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Pathologic diagnosis of ACC * Primary ACC arising from the head and neck * Unequivocal clinical and/or radiological evidence of metastatic disease * Patient ability and availability to comply with study protocol procedures. Exclusion Criteria: * ACC patients with local and/or regional recurrence without distant metastases * Primary ACC arising from any non-head and neck region (e.g., breast, lung, skin etc) * Insufficient data about previous medical history.
๐Ÿ’Š

What it tests

  • Standard of Care (Investigator Choice)
๐Ÿ“

Where

1 site
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy